Sectors & IndustriesHealthcare

Best Healthcare Stocks to Buy Now (2025)

Top healthcare stocks in 2025 ranked by overall Due Diligence Score. See the best healthcare stocks to buy now, according to analyst forecasts for the healthcare sector.

According to Due Diligence Score, the 3 best healthcare stocks to buy right now are:

Catalyst Pharmaceuticals (NASDAQ:CPRX) is the top healthcare stock with a Due Diligence Score of 76, which is 51 points higher than the healthcare sector average of 25. It passed 25 out of 33 due diligence checks and has strong fundamentals. Catalyst Pharmaceuticals has seen its stock return 54.45% over the past year, overperforming other healthcare stocks by 68 percentage points.

Catalyst Pharmaceuticals has an average 1 year price target of $33.40, an upside of 48.12% from Catalyst Pharmaceuticals's current stock price of $22.55.

Catalyst Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 5 analysts covering Catalyst Pharmaceuticals, 80% have issued a Strong Buy rating, 20% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Exelixis (NASDAQ:EXEL) is the second best healthcare stock with a Due Diligence Score of 75, which is 50 points higher than the healthcare sector average of 25. It passed 24 out of 33 due diligence checks and has strong fundamentals. Exelixis has seen its stock return 46.45% over the past year, overperforming other healthcare stocks by 60 percentage points.

Exelixis has an average 1 year price target of $36.21, an upside of 11.84% from Exelixis's current stock price of $32.38.

Exelixis stock has a consensus Buy recommendation according to Wall Street analysts. Of the 14 analysts covering Exelixis, 35.71% have issued a Strong Buy rating, 21.43% have issued a Buy, 42.86% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Neurocrine Biosciences (NASDAQ:NBIX) is the third best healthcare stock with a Due Diligence Score of 75, which is 50 points higher than the healthcare sector average of 25. It passed 25 out of 33 due diligence checks and has strong fundamentals. Neurocrine Biosciences has seen its stock return 6.15% over the past year, overperforming other healthcare stocks by 20 percentage points.

Neurocrine Biosciences has an average 1 year price target of $165.93, an upside of 11.57% from Neurocrine Biosciences's current stock price of $148.73.

Neurocrine Biosciences stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 15 analysts covering Neurocrine Biosciences, 46.67% have issued a Strong Buy rating, 33.33% have issued a Buy, 20% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 75 healthcare stocks that have issued dividends in the past year, the 3 healthcare stocks with the highest dividend yields are:

Enzo Biochem (NYSE:ENZ) has an annual dividend yield of 15.31%, which is 13 percentage points higher than the healthcare sector average of 2.13%.

Enzo Biochem's dividend payout ratio of -22.2% indicates that its high dividend yield might not be sustainable for the long-term.

Select Medical Holdings (NYSE:SEM) has an annual dividend yield of 10.3%, which is 8 percentage points higher than the healthcare sector average of 2.13%. Select Medical Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Select Medical Holdings's dividend has shown consistent growth over the last 10 years.

Select Medical Holdings's dividend payout ratio of 23.4% indicates that its high dividend yield is sustainable for the long-term.

Siga Technologies (NASDAQ:SIGA) has an annual dividend yield of 9.3%, which is 7 percentage points higher than the healthcare sector average of 2.13%.

Siga Technologies's dividend payout ratio of 50% indicates that its high dividend yield is sustainable for the long-term.

Healthcare stocks were down -0.11% in the last day, and up 3.21% over the last week. Revelation Biosciences was the among the top losers in the healthcare sector, dropping -23.84% yesterday.

Revelation Biosciences shares are trading lower after the company announced plans for a 1-for-16 reverse stock split.

Based on WallStreetZen's Valuation Score, the 3 most undervalued healthcare stocks right now are:

Exelixis (NASDAQ:EXEL) is the most undervalued healthcare stock based on WallStreetZen's Valuation Score. Exelixis has a valuation score of 86, which is 71 points higher than the healthcare sector average of 15. It passed 6 out of 7 valuation due diligence checks.

Exelixis's stock has gained 46.45% in the past year. It has overperformed other stocks in the healthcare sector by 60 percentage points.

Biogen (NASDAQ:BIIB) is the second most undervalued healthcare stock based on WallStreetZen's Valuation Score. Biogen has a valuation score of 86, which is 71 points higher than the healthcare sector average of 15. It passed 6 out of 7 valuation due diligence checks.

Biogen's stock has dropped -40.85% in the past year. It has underperformed other stocks in the healthcare sector by -27 percentage points.

Astrazeneca (NASDAQ:AZN) is the third most undervalued healthcare stock based on WallStreetZen's Valuation Score. Astrazeneca has a valuation score of 71, which is 56 points higher than the healthcare sector average of 15. It passed 5 out of 7 valuation due diligence checks.

Astrazeneca's stock has gained 3.69% in the past year. It has overperformed other stocks in the healthcare sector by 17 percentage points.